BOSTON — In what oncologists are calling a potential turning point in the fight against cancer, pharmaceutical companies Moderna and Merck announced Wednesday that their personalized mRNA cancer vaccine showed positive results in its first-ever late-stage clinical trial — a development that sent both companies’ stocks soaring and prompted a wave of cautious optimism from researchers who have been burned by promising cancer treatments before.

The vaccine, known as mRNA-4157/V940 (because nothing says “hope” like a alphanumeric designation), uses the same mRNA technology that powered COVID-19 vaccines to teach the immune system to recognize and attack melanoma cells. In the Phase 3 trial, which enrolled patients with high-risk Stage III and IV melanoma, the vaccine combined with Merck’s immunotherapy drug Keytruda reduced the risk of recurrence or death by 49% compared to Keytruda alone.

That number — 49% — is significant for reasons that go beyond statistics. Cancer researchers have spent decades trying to develop vaccines that work against established tumors, and most of those attempts have ended in what the industry politely calls “disappointing results” and what patients more accurately call “devastating.” A 49% reduction in recurrence is not a cure. But it is the kind of result that makes scientists who have spent their careers staring at cells under microscopes allow themselves, for the first time in a long time, to feel something resembling hope.

"This is the first time a personalized cancer vaccine has succeeded in a Phase 3 trial. The first time."

Dr. Ryan Weightman, the chief medical officer at Moderna, described the results as “a milestone for mRNA science and for cancer patients everywhere.” Weightman then clarified that “everywhere” included “everywhere except the internet, where people are already arguing about whether mRNA technology is safe,” which is the kind of thing that happens when you cure part of cancer and someone on social media asks if the vaccine turns you into a microwave.

The vaccine works by analyzing a patient’s tumor DNA to identify up to 34 unique mutations — the molecular fingerprint of that specific cancer — and then crafting a personalized mRNA sequence that teaches the immune system to recognize those mutations. In other words, it’s a vaccine定制 for each patient, which means the pharmaceutical industry has figured out how to make 8 billion unique versions of something and still charge $100,000 per dose.

mRNA CANCER VACCINE: BY THE NUMBERS

  • 49% — reduction in recurrence or death (Keytruda + vaccine vs. Keytruda alone)
  • 34 — unique mutations targeted per patient (personalized mRNA sequence)
  • 1 — Phase 3 cancer vaccine trial to succeed using mRNA technology (the first)
  • $100,000+ — estimated per-dose cost (because nothing says "affordable healthcare" like a six-figure injection)
  • 106 — days from first COVID vaccine dose to first cancer vaccine trial result (just kidding — it took four years, but it feels faster)
  • ∞ — amount of hope this gives to people who need it

The broader implications of the trial extend beyond melanoma. Moderna and Merck are already planning trials for other cancer types, including lung, bladder, and kidney cancer — each of which presents a different set of mutations and a different set of immunological challenges. If the mRNA approach works across multiple cancer types, it could fundamentally alter the landscape of oncology, shifting the paradigm from “treat the cancer” to “teach the body to fight the cancer,” which is a distinction that sounds subtle but is, in practice, the difference between mopping up a flood and turning off the faucet.

Cancer researchers outside the Moderna-Merck partnership were cautiously enthusiastic. Dr. Jennifer Li, a melanoma specialist at Memorial Sloan Kettering, called the results “genuinely exciting” but warned that “a 49% reduction is not a 100% reduction, and patients need to understand that.” Li then added that “if someone offers me a 49% better chance of not dying, I’ll take it,” which is the kind of medical opinion that doesn’t usually make it into the peer-reviewed literature but probably should.

"If someone offers me a 49% better chance of not dying, I'll take it."

The stock market, characteristically, responded to the cancer vaccine news by doing what the stock market does best: pricing in future expectations and then immediately second-guessing them. Moderna shares jumped 12% at the open before settling to a 7% gain, while Merck rose 4%. Analysts noted that the results were “priced in by smart money last week” and that “the retail investors buying now are approximately two news cycles late,” which is financial-speak for “you missed the boat, but at least the boat was heading somewhere good.”

At press time, a spokesperson for the American Cancer Society had issued a statement calling the results “a significant step forward” and urging patients to “speak with their oncologists about whether this treatment might be right for them,” which is medical-speak for “don’t get your hopes up on the internet, but also don’t stop hoping.”